Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 8/20 | 0.73 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | BACE1 | P56817 | 3/20 | 0.54 |
| ▸ | BCHE | P06276 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1022565 | 0.89 | ACHE (0.58) | ACHEHRH3BACE1BCHEKMT2A | |
| SCHEMBL1020725 | 0.84 | ACHE (1.00) | ACHEHRH3BCHEKMT2ALMNA | |
| SCHEMBL1904917 | 0.82 | ACHE (0.67) | ACHEHRH3KDM4EGAAKMT2A | |
| SCHEMBL2822514 | 0.82 | ACHE (0.67) | ACHEHRH3KDM4EGAABACE1 | |
| SCHEMBL3603394 | 0.80 | HRH3 (0.59) | ACHEHRH3KDM4EGAABACE1 | |
| SCHEMBL29640453 | 0.78 | SIGMAR1 (0.59) | SLC6A12SIGMAR1 | |
| SCHEMBL28742010 | 0.78 | SIGMAR1 (0.59) | SLC6A12SIGMAR1 | |
| SCHEMBL3359734 | 0.78 | DRD2 (0.71) | ACHEHRH3KDM4EGAABACE1 | |
| SCHEMBL22655135 | 0.77 | GAA (0.52) | ACHEKDM4EGAAKMT2ALMNA | |
| SCHEMBL29565663 | 0.77 | GAA (0.52) | ACHEKDM4EGAAKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101547915-B | Piperidinylamino-pyridazines and their use as fast dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV | 2013-08-21 | — | — | CN | disclosed |
| US-8466153-B2 | Piperidinylamino-pyridazines and their use as fast dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-06-18 | — | — | US | disclosed |
| US-8466153-B2 | Piperidinylamino-pyridazines and their use as fast dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-06-18 | — | — | US | disclosed |
| US-8466153-B2 | Piperidinylamino-pyridazines and their use as fast dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-06-18 | — | — | US | disclosed |
| EP-2091938-B1 | PIPERIDINYLAMINO-PYRIDAZINES AND THEIR USE AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-27 | — | — | EP | disclosed |
| EP-2091938-B1 | PIPERIDINYLAMINO-PYRIDAZINES AND THEIR USE AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-27 | — | — | EP | disclosed |
| US-20100076187-A1 | FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN-CILAG S.A. (ES) | 2010-03-25 | — | — | US | disclosed |
| US-20100076187-A1 | FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN-CILAG S.A. (ES) | 2010-03-25 | — | — | US | disclosed |
| US-20100076187-A1 | FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN-CILAG S.A. (ES) | 2010-03-25 | — | — | US | disclosed |
| CN-101547915-A | Piperidinylamino-pyridazines and their use as fast dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-30 | — | — | CN | disclosed |
| EP-2091938-A1 | PIPERIDINYLAMINO-PYRIDAZINES AND THEIR USE AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008068277-A1 | PIPERIDINYLAMINO-PYRIDAZINES AND THEIR USE AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008068277-A1 | PIPERIDINYLAMINO-PYRIDAZINES AND THEIR USE AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076187-A1 | FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | DRD2, GRIN2C, GRIN2A | ACHE 300/4885HRH3 1017/4885KDM4E 2783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.